Tirzepatide

CAS number:2023788-19-2

• Home
• Chemical products

---

• Molecular Formula:

  C225H348N48O68

• Molecular Weight:

  4813.45g/mol

• Brief Introduction:

  Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management. Clinical trials from the SURPASS and SURMOUNT series have demonstrated its superior efficacy in glycemic control and weight reduction compared to existing GLP-1 receptor agonists (Khurana et al., 2024). It has shown significant weight loss outcomes, with patients achieving up to 20.9% reduction in body weight at higher doses (Jastreboff et al., 2022, cited in Khurana et al., 2024). Additionally, tirzepatide has been effective in managing hypothalamic obesity, a condition typically refractory to standard treatments, as evidenced by a case report where a patient lost 9 kg over 4 months (Brijmohan & Mullally, 2025). Despite its benefits, tirzepatide is associated with gastrointestinal adverse effects such as nausea, vomiting, and pancreatitis, which are common but generally manageable (Khurana et al., 2024). Its safety profile continues to be monitored in real-world settings to ensure optimal therapeutic outcomes.

• Properities:

  Type	Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [4, 5]
  Administration	Subcutaneous injection once per week [4]
  Approved for	Type 2 diabetes (US, May 2022) [4]; Obesity or overweight (US, November 2023) [4]
  Doses (Clinical Trials)	5 mg, 10 mg, 15 mg [4]
  Common Doses (Real-world)	2.5 mg (initiation), 5 mg, 7.5 mg (by sixth prescription fill) [3]
  Effects on Weight	Significant weight reduction: 5% to 20.9% across different trials in a dose-dependent manner over 72 weeks [4]; Mean weight reduction of 12.9% at 6-months post-index in real-world use [5]; 22.5% mean bodyweight reduction at week 72 (15mg dose) in SURMOUNT-1 [4]; 21.1% mean bodyweight reduction over 72 weeks (10 or 15 mg) in SURMOUNT-3 [4]; 20.9% mean bodyweight reduction during 36-week lead-in, with an additional 6.7% over 52 weeks in SURMOUNT-4 [4].
  Effects on Body Composition	Lost body weight may be primarily due to fat mass reduction [4]; Associated with favorable changes in muscle fat infiltration and reductions in muscle volume [1].
  Effects on Appetite	Significantly decreased food intake, reduced overall appetite scores, and increased fasting visual analog scale scores for satiety and fullness [4].
  Effects on Glycemic Control	Favorable effects, with notable reductions in HbA1c levels ranging from 20.4 mmol/mol (5 mg dose) to 28.2 mmol/mol (15 mg dose) following 40-52 weeks of treatment [4].
  Effects on Lipid Profile	Beneficial impact, including reductions in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, while increasing high-density lipoprotein cholesterol concentrations [4].
  Adverse Effects	Associated with gastrointestinal adverse effects, requiring dose escalation strategies for tolerability [4]; Mild to moderate adverse events are commonly reported at higher doses [4]; Discontinuation rates due to adverse events range from 4% to 10% across different dosages [4].
  Persistence (Real-world)	Ranged from 60.6% to 75.7% across databases over 6 months [3].
  Marketed under the brand name	Mounjaro [5]

• References:

  [1] Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes & MetabolismMay 2025.

  [2] Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide. JHEP ReportsAvailable online 6 June 2025.

  [3] Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & EndocrinologyJune 2025.

  [4] The promise of tirzepatide: A narrative review of metabolic benefits. Primary Care DiabetesJune 2025.

  [5] Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States. Clinical TherapeuticsAvailable online 6 June 2025.

---

2023788-19-2 Suppliers

Inquiry: net.fei@163.com

Shenzhen Hanyu Pharmacy Co.,Ltd.

Shenzhen Hanyu Pharmaceutical Co., Ltd. (Hanyu Pharmaceutical for short) is a national high-tech enterprise established in 2003, focusing on the research and development, production and sales of peptide drugs. It was listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199).

Juncheng Pharmaceutical (Juancheng) Co., Ltd.

Juncheng Pharmaceutical (Juancheng) Co., Ltd. is located in Zone B of the API Innovation Incubation Park of Juancheng Chemical Industry Park, with an annual production capacity of 1,000 tons of bosine, telpotide, and semaglutide intermediates.

Fujian Genohope Biotech Ltd.

Fujian Genohope Biotech Ltd. focuses on the research, development, production and sales of peptide APIs and preparations, mainly promoting products such as semaglutide, covering the fields of diabetes treatment, weight loss and cardiovascular health. Its production line has an annual production capacity of 100 kilograms.